JAGUAR HEALTH, INC. Business Combination, Acquisition Related Costs
JAGUAR HEALTH, INC. (JAGX) reported Business Combination, Acquisition Related Costs of $3.55 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2018-11-19
- JAGUAR HEALTH, INC. business combination, acquisition related costs for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- JAGUAR HEALTH, INC. business combination, acquisition related costs for the quarter ending 2018-06-30 was $0.00.
- JAGUAR HEALTH, INC. business combination, acquisition related costs for the quarter ending 2018-03-31 was $3.55M.
- JAGUAR HEALTH, INC. business combination, acquisition related costs for the quarter ending 2017-12-31 was $0.00.
- JAGUAR HEALTH, INC. business combination, acquisition related costs for fiscal 2017 was $3.55M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-19 | $0.00 derived: sum of 2 quarters · filed 2018-11-19 | $3.55M 10-Q · filed 2018-11-19 | $3.55M derived: sum of 4 quarters · filed 2018-11-19 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $3.55M 10-Q · filed 2018-08-13 | $3.55M derived: sum of 3 quarters · filed 2018-08-13 | $4.66M derived: sum of 4 quarters · filed 2018-08-13 |
| 2018-03-31 | $3.55M 10-Q · filed 2018-05-15 | $3.55M derived: sum of 2 quarters · filed 2018-05-15 | $4.66M derived: sum of 3 quarters · filed 2018-05-15 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | $1.10M derived: sum of 2 quarters · filed 2018-04-09 | $3.55M 10-K · filed 2018-04-09 | |
| 2017-09-30 | $1.10M 10-Q · filed 2017-11-20 | $3.55M 10-Q · filed 2017-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |